And I read that the size of the team was 10 people - that's not a big number.
The compute power applied was not why they had this outcome.
"What is worse than academic groups getting scooped by DeepMind? The fact that the collective powers of Novartis, Pfizer, etc, with their hundreds of thousands (~million?) of employees, let an industrial lab that is a complete outsider to the field, with virtually no prior molecular sciences experience, come in and thoroughly beat them on a problem that is, quite frankly, of far greater importance to pharmaceuticals than it is to Alphabet. It is an indictment of the laughable “basic research” groups of these companies, which pay lip service to fundamental science but focus myopically on target-driven research that they managed to so badly embarrass themselves in this episode."
From: https://moalquraishi.wordpress.com/2018/12/09/alphafold-casp...
I think a lot of the commentary is missing two essential points:
1. Protein structure prediction is to a large extent a solved problem for small-ish, soluble targets. AlphaFold is a significant improvement on the current state of the art, but the state of the art was already far enough along that the best computational models in 2007 were good enough to bootstrap experimental structure determination (https://www.ncbi.nlm.nih.gov/pubmed/17934447). In other words, it's not like the entire academic community was stumbling around helplessly in the dark.
2. The value of these predictions to pharmaceutical companies is extremely marginal. Having a high-accuracy model is very helpful but it's rare that the researchers have so little information available that a completely de-novo prediction is necessary. And when they really don't have much information at all, it's usually because the target is sufficiently messy to defy traditional structure determination methods - which means it's almost certainly more than AlphaFold can handle too.
Without measurable benchmarks we have no idea if we're making real progress towards human level AI.